Abstract
Since its approval by the U.S. Food and Drug Administration in late January 2018, 177Lu-labeled DOTATATE (Lutathera; Advanced Accelerator Applications, a Novartis company) has been used for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors by
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have